Summary
The product Anastrozole 1 mg, manufactured by Unique Pharma, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number GH65721K, was submitted by the reseller Optitropin.EU and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Anastrozole, with a concentration of 0.82 mg per pill, which is 18% below the labeled claim of 1 mg.
The testing process began on 1 August 2022, with the sample received on 9 August 2022, and analysis completed on 12 August 2022. The results indicate underdosing, raising concerns about the consistency and reliability of the product. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Unique Pharma
- Product Name: Anastrozole 1 mg
- Active Ingredient: Anastrozole
- Batch Number: GH65721K
- Expiration Date: 03/2027
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #22607
- Testing Ordered: 1 August 2022
- Sample Received: 9 August 2022
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Optitropin.EU (Reseller)
- Analysis Paid For By: Optitropin.EU
Testing Results
- Specification: 1 mg per pill (as stated on the label)
- Measured Concentration: 0.82 mg per pill
- Accuracy: 82% (18% below the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/22607_QV1KJYFMNP54
Evaluation of Reseller-Submitted Testing
This analysis highlights a significant underdosing issue with the tested product. The sample was submitted and funded by the reseller Optitropin.EU, which may introduce potential biases. Resellers often select optimal batches for testing, which may not fully represent the consistency of products available to consumers. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple batches.
Conclusion
The analysis confirms that Anastrozole 1 mg is underdosed, with a measured concentration of 0.82 mg per pill. This result raises concerns about the quality control for this batch and underscores the importance of additional testing to ensure consistent dosing across the product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding pharmaceutical products.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
